PALYNZIQ is the first and only enzyme therapy approved to treat adults with PKU. BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.) Detailed results from the PEGASUS study will ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial. Hypochondroplasia is a form of skeletal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

By Agnes Chang and Josh Holder Prime Minister Benjamin Netanyahu of Israel, who is visiting Hungary despite facing an international arrest warrant, praised the move. By Andrew Higgins and ...

SAN RAFAEL, Calif. - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company with a market capitalization of $12.96 billion and impressive gross margins of nearly 80%, announced on ...